NovaBridge Biosciences (NBP) Key Metrics
NBP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $146.2M
- Enterprise value
- −$10.0M
- P/E (TTM)
- —
- Forward P/E
- 2.7
- PEG ratio
- —
- Price / sales
- 25.4
- Price / book
- 0.9 10-yr median 0.6
- EV / EBITDA
- 0.1
- Dividend yield
- —
- Beta
- 1.60
NBP key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNBP valuation Price multiples at each fiscal year-end price.
NBP returns How much profit the business earns on the capital it uses.
NBP per-share figures Results divided by the shares outstanding at year-end.
NBP financial health Debt, liquidity and how easily interest is covered.
NBP valuation history
NBP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NBP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NBP cash returned to shareholders
NBP price vs earnings per share
NBP key metrics
2017–2025| 2025 | 2024 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $165.7M | $69.0M | $3.22B | — | — | — |
| Enterprise value | $136.0M | −$1.17B | −$1.55B | — | — | — |
| P/E ratio | — | — | 6.8 | — | — | — |
| Price / sales | — | — | 2.1 | — | — | — |
| Price / book | 5.0 | 0.0 | 0.6 | — | — | — |
| Price / free cash flow | — | — | 7.6 | — | — | — |
| Price / operating cash flow | — | — | 7.4 | — | — | — |
| EV / sales | — | — | -1.0 | — | — | — |
| Earnings yield | −4.0% | −235.1% | 14.6% | — | — | — |
| Free cash flow yield | −12.4% | −557.6% | 13.2% | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 3.5% | 0.2% | — | — | — |
| Share price at fiscal year-end | $3.98 | $0.85 | $47.15 | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $22.57 | $0.52 | $0.92 | $0.19 |
| Earnings per share | −$0.16 | −$2.00 | $6.89 | −$24.89 | −$6.92 | −$5.13 |
| Operating cash flow per share | −$0.49 | −$4.73 | $6.34 | −$14.92 | −$4.83 | −$4.33 |
| Free cash flow per share | −$0.49 | −$4.74 | $6.22 | −$15.13 | −$5.07 | −$4.68 |
| Cash per share | $0.72 | $15.59 | $70.07 | $20.10 | $31.70 | $9.87 |
| Book value per share | $0.79 | $18.08 | $82.31 | $18.38 | −$16.42 | $7.06 |
| Tangible book value per share | $0.79 | $18.08 | $78.17 | $13.03 | −$21.77 | $1.70 |
| Dividends per share | — | — | — | $0.09 | — | — |
| Capex per share | $0.00 | $0.00 | $0.12 | $0.21 | $0.25 | $0.35 |
| Debt per share | $0.01 | $0.35 | $0.28 | $2.28 | $2.53 | $3.66 |
| Shares outstanding | 41.6M | 81.2M | 68.4M | 58.2M | 58.2M | 58.2M |
| Change in shares outstanding | −48.7% | +18.8% | +17.5% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −0.9% | −11.1% | 14.1% | — | — | −72.7% |
| Return on invested capital (ROIC) | −9.1% | −128.4% | 34.1% | — | — | −438.7% |
| Return on assets (ROA) | −0.8% | −10.5% | 11.7% | −70.4% | −23.7% | −29.1% |
| Return on tangible assets | −17.8% | −10.5% | 7.8% | −101.5% | −19.5% | −41.8% |
| Free cash flow margin | — | — | 27.6% | — | −548.7% | — |
| Income quality (OCF / net income) | — | — | 0.92 | — | — | — |
| Financial health | ||||||
| Total debt | $438,458 | $28.3M | $19.1M | $132.5M | $147.0M | $213.0M |
| Cash & short-term investments | $30.1M | $1.27B | $4.79B | $1.17B | $1.84B | $574.2M |
| Net debt | −$29.7M | −$1.24B | −$4.77B | −$1.04B | −$1.70B | −$361.2M |
| Debt / equity | 0.01 | 0.02 | 0.00 | 0.12 | — | 0.52 |
| Debt / assets | 0.01 | 0.02 | 0.00 | 0.08 | 0.06 | 0.21 |
| Net debt / EBITDA | — | — | −28.35 | — | — | — |
| Current ratio | 8.09 | 20.90 | 9.28 | 2.31 | 5.88 | 3.54 |
| Quick ratio | 8.09 | 20.90 | 9.28 | 2.41 | 6.51 | 3.54 |
| Interest coverage | — | — | — | — | -268.1 | -316.9 |
| Working capital | $27.3M | $1.23B | $4.77B | $772.8M | $1.69B | $496.4M |
| Invested capital | $3.3M | $231.0M | $856.0M | $32.5M | −$2.65B | $49.3M |
| Tangible asset value | $33.0M | $1.47B | $5.34B | −$2.35B | −$1.27B | −$611.2M |
| Net current asset value | $26.9M | $1.21B | $4.63B | −$2.41B | −$1.29B | −$633.5M |
| Graham number | — | — | $112.95 | — | — | — |
| Graham net-net per share | $0.63 | $14.63 | $63.58 | −$44.51 | −$27.29 | −$12.86 |
| Capital allocation | ||||||
| Dividends paid | — | — | — | $5.3M | — | — |
| Share buybacks (net) | $0 | $2.4M | $5.3M | — | — | — |
| Dividends + buybacks / free cash flow | — | — | 1.3% | — | — | — |
| Capex / revenue | — | — | 0.5% | 40.8% | 26.8% | 180.4% |
| Capex / operating cash flow | — | — | 1.8% | — | — | — |
| Capex / depreciation | 0.01 | 0.05 | 0.35 | 0.78 | 2.14 | 12.44 |
| Stock-based compensation / revenue | — | — | 32.0% | 1,223.0% | 6.5% | 62.5% |
| R&D / revenue | — | — | 63.8% | 2,801.4% | 792.2% | 2,370.8% |
| SG&A / revenue | — | — | 26.1% | 2,181.8% | 123.4% | 225.8% |
| Efficiency | ||||||
| Days sales outstanding | — | — | 48.9 | 393.2 | 45.9 | 134.4 |
| Receivables turnover | 0.00 | 0.00 | 7.47 | 0.93 | 7.96 | 2.72 |
| Asset turnover | 0.00 | 0.00 | 0.38 | 0.01 | 0.03 | 0.01 |
| Average receivables | $4.4M | $8.6M | $206.6M | $32.3M | $6.8M | $4.1M |
| Average inventory | — | — | — | −$135.7M | −$215.6M | — |
| Intangibles / total assets | 0.0% | 0.0% | 4.5% | 17.9% | 13.1% | 30.4% |
Computed from NBP's annual financial statements (latest annual report filed April 7, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NBP valuation and financial ratios
NovaBridge Biosciences earned a return on equity of −0.9% and a return on invested capital of −9.1% in fiscal 2025. It ended the year with $0.4 million of debt and $30.1 million in cash and short-term investments, a net cash position of $29.7 million. The share count fell 28.4% from 58.2M to 41.6M over 5 years.
See the NBP income statement, the NBP chart for price history, or the NBP stock overview for the latest quote and news.
NBP key metrics FAQ
What is NovaBridge Biosciences's return on equity?
NovaBridge Biosciences's return on equity (ROE) was −0.9% in fiscal 2025: net income of -$6.6 million on average shareholders' equity of $750.6 million.
What is NovaBridge Biosciences's ROIC?
NovaBridge Biosciences's return on invested capital was −9.1% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does NovaBridge Biosciences have?
NovaBridge Biosciences had total debt of $0.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is NovaBridge Biosciences's free cash flow yield?
NovaBridge Biosciences generated -$20.6 million of free cash flow in fiscal 2025, a free cash flow yield of −12.4% on its market value at year-end ($165.7 million).
What is NovaBridge Biosciences's current ratio?
NovaBridge Biosciences's current ratio was 8.09 at the end of fiscal 2025: current assets were 8.09 times current liabilities.